Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 48, 2014 - Issue 1
Journal homepage
388
Views
21
CrossRef citations to date
0
Altmetric
Review

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Rafal TuroDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UKCorrespondence[email protected]
,
Michal SmolskiDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Rachel EslerDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Magda L. KujawaDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Stephen J. BromageDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Neil OakleyDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Adebanji AdeyojuDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Stephen C. W. BrownDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Richard BroughDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
,
Andrew SinclairDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
&
Gerald N. CollinsDepartment of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK
 show all
Pages 4-14 | Received 18 Jul 2013, Accepted 22 Oct 2013, Published online: 21 Nov 2013
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later
PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.